Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap

July 16, 2025

Government price negotiations under the Inflation Reduction Act may hinder biosimilar development, impacting drug costs and patient access to affordable therapies.

FDA Approves Kirsty as First Interchangeable Insulin Aspart Biosimilar

July 15, 2025

White Paper Offers Tips for Sustaining Biosimilar Progress, Avoiding a Market Void

July 15, 2025

BioRationality: How the FDA Can Bypass Congress to Change Biosimilar Guidance

July 14, 2025

Balancing Cost Savings With Clinical Practice for Multiple Myeloma Biosimilars: Tyler Sandahl, PharmD

July 14, 2025

The Top 5 Biosimilar Articles for the Week of April 17

April 21st 2023

By Justina Petrullo

Video

Here are the top 5 biosimilar articles for the week of April 17, 2023.

Multiple Infliximab Biosimilar Switches Appear Safe, Effective for Patients With IBD

April 20th 2023

By Justina Petrullo

Article

A retrospective study in Scotland found that multiple successive changes from originator infliximab to biosimilars seem to be safe and effective in patients with inflammatory bowel disease (IBD), irrespective of the number of switches.

Study Reveals Factors That Dissuade Commercial Plans From Covering Biosimilars

April 19th 2023

By Skylar Jeremias

Article

A study assessing factors that may determine a commercial health plan’s likelihood of covering a biosimilar found that biosimilars that are cancer therapies, used to treat children, indicated for highly prevalent conditions, or only competing against the originator were more likely to have coverage restrictions.

Similar Overall Survival, Shorter Progression-Free Survival With Rituximab Biosimilar in Patients With DLBCL vs Originator

April 18th 2023

By Deana Ferreri, PhD

Article

Authors of a single-center, real-world study in Turkey found that patients with diffuse large B-cell lymphoma (DLBCL) who received a rituximab biosimilar had similar overall survival to patients who received the originator. However, progression-free survival was longer in the originator group.

BioRationality: FDA Final Guidance on Continuous Manufacturing—A Boon for Biosimilars

April 17th 2023

By Sarfaraz K. Niazi, PhD

Article

The misconceptions about disposable bioreactors' lifecycle are gone; the era of hard-piped, giant, stainless-steel tanks for biosimilar development is history now, according to Sarfaraz K. Niazi, PhD, in his latest column.

Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars

April 16th 2023

By Skylar Jeremias

Podcast

What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.

Real-World Study Suggests Comparable Efficacy Between Biosimilar Razumab and Originator in PCV

April 15th 2023

By Deana Ferreri, PhD

Article

A real-world study in India compared the ranibizumab biosimilar Razumab to the originator (Lucentis) in patients with polypoidal choroidal vasculopathy (PCV), finding that the biosimilar had comparable clinical outcomes.

FDA Issues Another CRL for Alvotech’s Adalimumab Biosimilar

April 14th 2023

By Skylar Jeremias

Article

In a complete response letter (CRL) for Alvotech, the FDA cited “deficiencies” in the company’s manufacturing facility during a reinspection, further delaying the approval for the ninth adalimumab biosimilar until potentially June 2023.

The Top 5 Biosimilar Articles for the Week of April 10

April 14th 2023

By Justina Petrullo

Video

Here are the top 5 biosimilar articles for the week of April 10, 2023.

Kathy Oubre Discusses PBM, Payer Challenges for Biosimilar Adoption

April 13th 2023

By Pearl Steinzor

Article

Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, discusses the use of biosimilars and how pharmacy benefit managers (PBMs) as well as payers have challenged the biosimilar market.